Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer

Published:2017-04-08 Issue:7 Volume:66 Page:891-901
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Lilleby Wolfgang^ORCID,Gaudernack Gustav,Brunsvig Paal F.,Vlatkovic Ljiljana,Schulz Melanie,Mills Kate,Hole Knut Håkon,Inderberg Else Marit

Funder

This study was supported by The Norwegian Research Council (FORNY program), Innovation Norway AS, Ultimovacs AS.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/article/10.1007/s00262-017-1994-y/fulltext.html

Reference27 articles.

1. Lilleby W, Hernes E, Wæhre H, Raabe N, Fosså SD (2006) Treatment of hormone-resistant prostate cancer. Tidsskr Nor Laegeforen 126:2798–2801

2. Lilleby W, Narang A, Tafjord G, Vlatkovic L, Russnes KM, Stensvold A, Hole KH, Tran PT, Eilertsen K (2015) Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy. Radiat Oncol 10:232–237. doi: 10.1186/s13014-015-0540-3

3. Kyte JA (2009) Cancer vaccination with telomerase peptide GV1001. Expert Opin Investig Drugs 18:687–694

4. Su Z, Dannull J, Yang BK et al (2005) Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 174:3798–3807

5. Zanetti M (2017) A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nat Rev Clin Oncol 14:115–128. doi: 10.1038/nrclinonc.2016.67

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Telomere-related DNA damage response pathways in cancer therapy: prospective targets;Frontiers in Pharmacology;2024-06-07

2. Identification of tumor antigens for mRNA vaccines and ferroptosis-related landscape in esophageal squamous cell carcinoma;Translational Cancer Research;2024-06

3. Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer;Molecular Therapy;2024-06

4. Understanding, diagnosing, and treating pancreatic cancer from the perspective of telomeres and telomerase;Cancer Gene Therapy;2024-04-09

5. The bright side of chemistry: Exploring synthetic peptide‐based anticancer vaccines;Journal of Peptide Science;2024-04-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3